The study, which tracked 29 participants with Claudin 6-positive (CLDN6+) tumors, reported a 92.9% disease control rate among the group. Patients involved in the trial had previously undergone a median of two lines of therapy, including platinum-based chemotherapy and PARP inhibitors. Researchers observed clinical responses even in patients who had already failed prior treatments like mirvetuximab soravtansine, suggesting the therapy may offer a new avenue for those with limited options.

Safety data indicated a manageable profile for the drug combination. Investigators reported no instances of clinically significant bleeding, bowel perforation, or ocular events, which have historically complicated therapies in this category. TORL BioTherapeutics CEO Aran Maree noted that these findings reinforce the potential of the drug, known as Ixo-V, to serve as a partner for existing standards of care. The company is now focused on the global CATALINA-2 registrational study, with pivotal results expected by mid-2027.